Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Phibro Animal Health Corporation (PAHC) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Phibro Animal Health Corporation (PAHC) - free report >>
Image: Bigstock
Phibro Animal Health Hurt by Threats of Mecadox Suspension
On Sep 13, we issued an updated research report on NJ-based Phibro Animal Health Corporation (PAHC - Free Report) – a leading global diversified animal health and mineral nutrition company. The company currently carries a Zacks Rank #5 (Strong Sell).
Over the last 30 days, the Zacks Consensus Estimate for full-year 2016 earnings fell by 27 cents to $1.41 per share, as most analysts revised their estimates downward.
PHIBRO ANIMAL Price and Consensus
PHIBRO ANIMAL Price and Consensus | PHIBRO ANIMAL Quote
Notably, after ending the fourth quarter of fiscal 2016 on an unsatisfactory note with deteriorating year-over-year earnings, the biggest concern for the company has been the initial actions taken by the FDA to withdraw approval for its flagship product Mecadox.
Notably, Mecadox is a carbadox product sold by Phibro for more than 40 years. Per management, the FDA withdrawal is expected to impact the company’s operations over the long haul.
Other major dampeners for Phibro are an unsatisfactory performance by its mineral nutrition segment in the last reported quarter, currency fluctuations, consolidation of the company’s customers which is increasing pricing pressure and a tough competitive market scenario.
On a positive note, the encouraging global trends in the animal health market buoy optimism for the company. Notably, Phibro is a leading provider of Medicated Feed Additives (MFA) and data by Vetnosis suggests that the MFA product market is projected to grow at a CAGR of approximately 4% (from 2015–2020).
Key Picks
Better-ranked stocks in the broader medical sector include INC Research Holdings Inc. (INCR - Free Report) , Lantheus Holdings Inc (LNTH - Free Report) and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>